Overview: Cardio IQ Lipoprotein Fraction TestIntroduction: The Cardio IQ Lipoprotein Fraction Test analyzes lipoprotein particles to assess heart disease risk, causing chest pain or shortness of breath. Aligned with 2023 AHA guidelines, it uses an immunoassay for high sensitivity, aiding in cardiovascular screening. This test is critical for guiding risk assessment, preventive strategies, and improving outcomes in biochemistry for patients with suspected cardiovascular conditions.
Other Names: Cardio IQ Assay, Lipoprotein Subfraction Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Lipoprotein fractionation began in the 1980s with lipid profiling. Advanced immunoassays emerged in the 2000s, and by the 2010s, high-sensitivity assays improved heart disease risk assessment.
Purpose: Assesses heart disease risk, guides preventive measures, and monitors lipoprotein profiles in patients with chest pain or shortness of breath.
Test Parameters: 1. Lipoprotein Fractionation
Pretest Condition: Fasting for 10-12 hours required to stabilize lipid levels. Collect serum or plasma after overnight fasting. Report symptoms like chest pain or shortness of breath, and list medications like statins.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document cardiovascular symptoms, family history of heart disease, or lipid disorders. Include current medications, especially statins or fibrates.
Consent: Written consent required, detailing the tests purpose, implications for heart disease risk, and potential need for lipid-lowering therapy.
Procedural Considerations: Uses an immunoassay to analyze lipoprotein particles. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Non-fasting samples or lipid-lowering medications may alter results. Hemolysis or improper storage can degrade samples.
Clinical Significance: Abnormal lipoprotein profiles indicate increased heart disease risk, prompting lifestyle changes or statin therapy. Normal profiles support ongoing monitoring.
Specialist Consultation: Consult a cardiologist for result interpretation. A lipidologist referral is advised for complex dyslipidemia cases.
Additional Supporting Tests: Lipid profile, Apo B test, or hs-CRP to assess cardiovascular risk comprehensively.
Test Limitations: Results may not fully predict heart disease risk without clinical correlation. Integration with other lipid markers is required.
References: AHA Lipid Guidelines, 2023; Circulation, Grundy SM, 2022.
